In CRC, several CSC-specific markers, such as leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), CD44, and CD133, have been identified as indicators of tumor aggressiveness and poor clinical outcomes [22,23,24]. Here, PROM1 is linked to neoplasm.